Prestige sumer Healthcare (US:PBH)2025-05-08 11:28FY25 Performance Recap - Record revenue of $1.138 billion, up 1.1% versus prior year[8] - Adjusted Diluted EPS up 7.3% versus prior year[8] - $52 million in FY25 share repurchases[8] Financial Highlights - Q4 Revenue of $296.5 million, up 7.0% vs prior year on an organic basis[33] - Q4 Adjusted EBITDA of $104.4 million compared to $90.4 million prior year[33] - Q4 Adjusted EPS of $1.32, up 28.7% compared to $1.02 prior year[33] - Full year Adjusted EBITDA of $374.5 million compared to $373.9 million prior year[32] - Gross Margin of 55.8% consistent with expectations[35] - A&M of 13.7% of Revenue[38] - G&A of 9.5% of Revenue[38] FY26 Outlook - Revenues of $1.140 to $1.155 billion[48] - Organic growth of approximately 1% to 2%, excluding projected FX headwind[48] - Diluted EPS of $4.70 to $4.82[48] - Free Cash Flow of $245 million or more[48]